Several members have been described and Aurora kinase A has been identified as a target for glioblastoma therapy, especially because specific inhibitors exist (alisertib, MLN8237) that have shown limited single-agent efficacy in orthotopic GBM model systems. The gene discussed is AURKA; the disease is glioblastoma.